| Literature DB >> 32636245 |
Jeffrey A Freiberg1, Yoann Le Breton2, Janette M Harro3, Devon L Allison3, Kevin S McIver2, Mark E Shirtliff3,4.
Abstract
Bacterial biofilms are responsible for a variety of serious human infections and are notoriously difficult to treat due to their recalcitrance to antibiotics. Further work is necessary to elicit a full understanding of the mechanism of this antibiotic tolerance. The arginine deiminase (ADI) pathway is responsible for bacterial pH maintenance and is highly expressed during biofilm growth in multiple bacterial species. Using the group A Streptococcus (GAS) as a model human pathogen, the ADI pathway was demonstrated to contribute to biofilm growth. The inability of antibiotics to reduce GAS populations when in a biofilm was demonstrated by in vitro studies and a novel animal model of nasopharyngeal infection. However, disruption of the ADI pathway returned GAS biofilms to planktonic levels of antibiotic sensitivity, suggesting the ADI pathway is influential in biofilm-related antibiotic treatment failure and provides a new strategic target for the treatment of biofilm infections in GAS and potentially numerous other bacterial species.IMPORTANCE Biofilm-mediated bacterial infections are a major threat to human health because of their recalcitrance to antibiotic treatment. Through the study of Streptococcus pyogenes, a significant human pathogen that is known to form antibiotic-tolerant biofilms, we demonstrated the role that a bacterial pathway known for responding to acid stress plays in biofilm growth and antibiotic tolerance. This not only provides some insight into antibiotic treatment failure in S. pyogenes infections but also, given the widespread nature of this pathway, provides a potentially broad target for antibiofilm therapies. This discovery has the potential to impact the treatment of many different types of recalcitrant biofilm infections.Entities:
Keywords: Streptococcus pyogeneszzm321990; antibiotic tolerance; arginine deiminase; biofilms; group A Streptococcuszzm321990
Mesh:
Substances:
Year: 2020 PMID: 32636245 PMCID: PMC7343988 DOI: 10.1128/mBio.00919-20
Source DB: PubMed Journal: mBio Impact factor: 7.867
FIG 1Comparison of WT and Arc mutant GAS during planktonic and biofilm growth. (A) Number of CFU/ml of the WT and arc mutant strains at indicated time points after inoculation of a planktonic culture in THY-B both with and without supplementation with 10 mM l-arginine. (B) Representative cross sections of WT and arc mutant biofilms formed on unbuffered THY-A after 144 h. The white bar represents 100 μm. (C) Maximum biofilm thickness measured as outlined in Materials and Methods using either COMSTAT2 or ImageJ to analyze images obtained by confocal microscopy at the indicated time points. (D to F) Number of CFU/ml of the WT and arc mutant strains at indicate time points after inoculation of a biofilm culture on THY-A plates with and without supplementation with 10 mM l-arginine. (D) Unbuffered THY-A with and without supplementation with 10 mM l-arginine. (E) THY-A buffered at pH 7.5. (F) THY-A buffered at pH 6.5 with and without supplementation with 10 mM l-arginine. Data presented represent the means ± standard deviations (SD). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
FIG 2Penicillin tolerance of WT and Arc mutant GAS. Planktonic cultures of the WT strain and arc mutant were grown either to mid-log phase (approximately 4 to 5 h) (A) or for 24 h (B) and exposed to the indicated concentrations of penicillin (PEN) for 4 and 24 h. (C to H) Biofilm cultures of the WT strain and arc mutant (C and E to H) or the WT strain, arc mutant, WT-NC, and arc mutant rescue strain (D) were grown for 48 h and exposed to the indicated concentrations of penicillin for 4 and 24 h. (E and F) Biofilm cultures of the WT and arc mutant strains were grown for 48 h and exposed to the following concentrations of the indicated antibiotic for either 4 h (E) or 24 h (F): AMP (ampicillin, 5 μg/ml), CFP (cefoperazone, 150 μg/ml), RIF (rifampin, 7 μg/ml), ERY (erythromycin, 2 μg/ml), and CLI (clindamycin, 14 μg/ml). (G and H) Biofilm cultures of the WT and arc mutant strains were grown for 48 h on either THY-AL-arg, THY-A7.5, THY-A6.5, or THY-A6.5+L-arg and then exposed to 20 μg/ml penicillin G for either 4 h (G) or 24 h (H). Data presented represent the means ± SD from three independent experiments measuring either the log10 fold reduction in CFU versus an untreated culture (log fold reductionuntreated or log fold reductionbiofilm). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
FIG 3Colonization of C57BL/6 IL-17A−/− mouse nasal tissues in the NALT infection model and penicillin tolerance. Nasal tissues harvested from mice at 1 day postinoculation (dpi) were cryosectioned and stained with FITC-conjugated anti-GAS antibody (green) and DAPI (blue) to visualize the formation of GAS microcolonies within the NALT of C57BL/6 IL-17A−/− mice inoculated with either WT-NC (A) or the arc mutant (B). (C) Nasal tissues were harvested at the indicated time points and cultured to determine the total number of CFU/mouse present. n = 6 mice per bacterial strain per time point. Mice inoculated intranasally with WT-NC or the arc mutant were treated with penicillin G or a placebo. (D) Nasal tissues were harvested 2 days after treatment (5 dpi) and cultured to determine the total number of CFU/mouse present. (E) Mice were determined to have cleared the infection if their CFU count was below the limit of detection (33 CFU/mouse). n = 20 to 22 mice per group. Data represent the combination of 5 independent experiments. Statistical significance was determined by a two-tailed Fisher’s exact test. *, P < 0.05; n.s., not significant.